Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Drops By 19.7%

Neuronetics, Inc. (NASDAQ:STIM) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 487,400 shares, a decline of 19.7% from the November 30th total of 607,300 shares. Based on an average trading volume of 431,600 shares, the days-to-cover ratio is currently 1.1 days. Approximately 3.1% of the company’s shares are short sold.

Neuronetics Trading Up 4.2 %

Shares of STIM traded up $0.06 during trading hours on Friday, hitting $1.48. 174,396 shares of the stock traded hands, compared to its average volume of 292,833. The business has a fifty day moving average of $1.08 and a 200-day moving average of $1.24. The firm has a market capitalization of $44.92 million, a PE ratio of -1.20 and a beta of 2.25. Neuronetics has a 1-year low of $0.52 and a 1-year high of $5.07. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP grew its position in shares of Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after buying an additional 30,837 shares during the period. HighTower Advisors LLC grew its holdings in Neuronetics by 55.5% during the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after acquiring an additional 87,816 shares during the period. First Eagle Investment Management LLC grew its holdings in Neuronetics by 33.4% during the 2nd quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock worth $1,870,000 after acquiring an additional 260,000 shares during the period. Acadian Asset Management LLC raised its position in shares of Neuronetics by 23.7% during the 2nd quarter. Acadian Asset Management LLC now owns 326,975 shares of the company’s stock valued at $587,000 after acquiring an additional 62,628 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC lifted its stake in shares of Neuronetics by 97.1% in the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 95,880 shares of the company’s stock valued at $173,000 after purchasing an additional 47,228 shares during the period. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.